Self Titration With Apidra to Reach Target Study (START)

Inclusion criteria: Run-in phase: * T2DM * Treated for at least 3 months with a basal insulin (insulin glargine, NPH, detemir) +/- oral antidiabetic drugs (OADs) with an HbA1c \>7.0% or insulin naive (2-3 OADs) with an HbA1c \>=7.8% (historic HbA1c result up to 3 months of screening is acceptable) Randomized treatment phase: * Completed run-in phase * HbA1c \>7.0% and \>= 1 episode of confirmed nocturnal hypoglycemia (BG \<4.0 mmol/L) or \>= 2 measurements of FG \<=6.0 mmol/L within the previous week Patients who completed the run-in phase with HbA1c \>7.0% and did not meet the randomization criteria will continue titrating insulin glargine and be followed until the end of study. Exclusion Criteria: * No food intake before lunch (noon) * Unstable diet intake or significant changes to current diet regimen * Nightshift worker * Type 1 Diabetes Mellitus * Subjects unwilling to inject insulin or perform self-monitoring blood glucose * Pregnant, alcohol or drug abuse * Active cancer or any other disease or condition which in the opinion of the investigator would make the subject unsuitable for participation in the study * Any clinical significant laboratory findings that in the judgment of the investigator would preclude safe completion of the study * Known allergies to study drugs The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.